Literature DB >> 9872221

Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.

N J Vander Els1, V Miller.   

Abstract

Gemcitabine is a nucleoside analog that is useful in the treatment of solid tumors. Its use has been postulated to produce lung injury by causing a capillary leak syndrome. We describe a gemcitabine-treated female patient who developed severe dyspnea, diffuse pulmonary infiltrates, and hypoxia, with evidence of interstitial disease on pulmonary function tests. Following the administration of oral corticosteroids, she had complete resolution of all signs and symptoms of gemcitabine toxicity. Physicians should be aware of this treatable complication of gemcitabine therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872221     DOI: 10.1378/chest.114.6.1779

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine.

Authors:  Silvia Antolín; Lourdes Calvo; Diana Dopico; María Quindós; Margarita Reboredo; Alberto Carral
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 2.  Anticancer Drug-Induced Capillary Leak Syndrome.

Authors:  Hassan Izzedine; Alexis Mathian; Zahir Amoura; Jia H Ng; Kenar D Jhaveri
Journal:  Kidney Int Rep       Date:  2022-02-25

3.  A report on serious pulmonary toxicity associated with gemcitabine-based therapy.

Authors:  Debasish F Roychowdhury; Catherine A Cassidy; Patrick Peterson; Michael Arning
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

4.  Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.

Authors:  Emilio Esteban; Noemi Villanueva; Isabel Muñiz; Yolanda Fernández; Joaquin Fra; Maria Luque; Paula Jiménez; Beatriz Llorente; Marta Capelan; José M Vieitez; Enrique Estrada; José M Buesa; Angel Jiménez-Lacave
Journal:  Invest New Drugs       Date:  2007-09-05       Impact factor: 3.850

Review 5.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

Review 6.  Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management.

Authors:  Stergios Boussios; George Pentheroudakis; Konstantinos Katsanos; Nicholas Pavlidis
Journal:  Ann Gastroenterol       Date:  2012

Review 7.  Diagnosis and management of drug-associated interstitial lung disease.

Authors:  N L Müller; D A White; H Jiang; A Gemma
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

8.  Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.

Authors:  Célia Turco; Marine Jary; Stefano Kim; Mélanie Moltenis; Bruno Degano; Philippe Manzoni; Thierry Nguyen; Bruno Genet; Marie-Blanche Valnet Rabier; Bruno Heyd; Christophe Borg
Journal:  Clin Med Insights Oncol       Date:  2015-09-01

9.  Gemcitabine-induced chronic systemic capillary leak syndrome.

Authors:  Ravneet Bajwa; Jason Starr; Karen Daily
Journal:  BMJ Case Rep       Date:  2017-08-30

Review 10.  First line Immunotherapy for Non-Small Cell Lung Cancer.

Authors:  Nicola J Nasser; Miguel Gorenberg; Abed Agbarya
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.